Just reported
From Resmed's results release of 29. Oktober 2026; its quarterly report has since been filed.
Actual
1,41B $
+5,9 % y/y
-3,3 % q/q
Guided
—
No guide given
Actual
2,92 $
+23 % y/y
+11 % q/q
Guided
—
No guide given
Actual
453M $
+1,4 % y/y
+1,0 % q/q
Guided
—
No guide given
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Resmed is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Die Umsatzanteile sind Schätzungen für quarter ended 2026-03-31 und keine Zahlen aus einem eingereichten Bericht.
AirSense 11
A connected machine that delivers continuous or automatically adjusted air pressure to treat sleep apnea.
AirCurve 11
A bilevel breathing machine that provides different pressure levels for breathing in and out, for people needing more support or with complex breathing disorders.
Astral ventilators
Ventilators that provide breathing support, including for people receiving care at home.
AirTouch N30i, AirTouch F30i, and AirFit F40 masks
Masks that connect a person to a breathing machine during sleep; the named models include fabric and silicone designs.
myAir and AirView
Software for patients to engage with their sleep treatment and for providers to connect with and support patients.
Brightree and MEDIFOX DAN
Software products for residential care and home medical equipment providers.
ResMed makes devices that help people breathe during sleep and ventilators for people who need breathing support. It also sells masks and software for patients, medical equipment providers, and residential care providers. Its sleep products include machines that connect with patient and provider software.
Gebaut aus den eigenen Einreichungen von Resmed Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
238,99 $+0,2 %Schluss 12. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 30. Oktober 2026
ResMed sells breathing machines and masks for sleep apnea and other breathing disorders to patients through medical equipment providers.
Grade B+
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 41 Quartalen der Notenhistorie von Resmed Inc.. Die übrigen 39 reichen zurück bis Oktober 2016.